Biotech Values

[DewDiligence]

DCGN is nearing the end of the road:

http://finance.yahoo.com/news/deCODE-genetics-Announces-prnews-14804935.html

At December 31, 2008, the company had liquid funds available for operating activities, comprised of cash and cash equivalents together with current investments, of $3.7 million, compared to $64.2 million at December 31, 2007. In early 2009, the company sold its auction rate securities (ARS) for $11.0 million in cash which the company has been using to finance its operating activities. The company believes it has sufficient resources to sustain operations only into the second quarter of this year.

It’s already the second quarter.